Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. Mai 2025 06:00 ET | Quelle: Artax Biopharma

Artax Biopharma presents Phase 2a results for oral Nck modulator AX-158 in late-breaking session at the Society for Investigative Dermatology 2025 Annual Meeting

First small molecule to modulate the fundamental mechanism of T cell activation underlying autoimmune pathology Statistically significant improvements in T cell and psoriasis-related biomarkers...
23. April 2025 12:00 ET | Quelle: Artax Biopharma

Artax Biopharma to present Phase 2a data on Nck modulator AX-158, establishing novel mechanism of action in autoimmune disease at the 2025 SID Annual Meeting

Late breaker abstract presentation to showcase clinical validation of first-in-class oral small molecule AX-158 in cohort of patients with psoriasis Full dataset to expand on previously announced...
07. März 2025 12:09 ET | Quelle: Artax Biopharma

Artax Biopharma Presents New Preclinical Data on Nck Modulators at 2025 AAD Annual Meeting

Nck modulator reduced evidence of inflammation in an animal model of dermal irritation Compelling preclinical data support continued development of Nck modulators in atopic dermatitis CAMBRIDGE,...
03. März 2025 09:00 ET | Quelle: Artax Biopharma

Artax Biopharma to present on first-in-class Nck modulator at the 2025 AAD Annual Meeting

CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces an...